BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth TheFly reported on March 11 that BTIG gave IBRX a Buy rating and assigned a $13 price target. The firm pointed to the stock's strong performance in 2026, supported by rapid year-over-year growth in U.S. ANKTIVA sales, conditional marketing authorization in the European Union, and NSCLC approval in Saudi Arabia. BTIG also said additional upside could come from continued commercial progress for ANKTIVA and potential expansion of its approved uses. Additionally, on March 13, 2026, ImmunityBio, Inc. (NASDAQ:IBRX) announced it had completed its NK2022 and NK2023 manufacturing engineering programs, advancing a leukapheresis-to-production process for its autologous memory cytokine-enhanced natural killer cell therapy platform. The company also said a Phase 1 study combining M-ceNK with ANKTIVA in relapsed or refractory tumor patients was completed and showed the treatment was well-tolerated after infu
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary TumorsBusiness Wire
- Lightning Round: I can't recommend Stellantis, says Jim Cramer [CNBC]CNBC
- ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference [Yahoo! Finance]Yahoo! Finance
- ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion [Seeking Alpha]Seeking Alpha
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 2/26/26 - Form 4
- 2/25/26 - Form SCHEDULE
- 2/24/26 - Form 4
- IBRX's page on the SEC website